Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects
Prescrire International 12(67): 179
2003
ISSN/ISBN: 1167-7422 PMID: 14619897 Document Number: 558741
There is no evidence that sublingual selegiline reduces the risk of adverse effects associated with oral selegiline. On the contrary, it has a potential for oral ulceration and stomatitis
Document emailed within 1 workday
Related Documents
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-472002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
2003: Paracetamol for injection: new formulation. New formulation: why so widely used? Prescrire International 12(67): 178
Ahrén, T.; Lithell, H.; Victor, A.; Vessby, B.; Johansson, E.D. 1981: Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II. Serum lipoproteins and apolipoproteins Contraception 24(4): 451-468
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Winkler, M.; Haller, G.; Oldhafer, K.; Bechstein, W.O.; Kattner, A.; Maibücher, A.; Färber, L.; Ringe, B.; Christians, U.; Neuhaus, P.; Pichlmayr, R. 1996: A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients Transplantation 62(8): 1063-1068
Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Szabo, K.A.; Schaff, E.A. 2013: Oral contraceptives: does formulation matter? Journal of Family Practice 62(10): E1-12
Sparkman, H.E. 1979: Experience with cimetidine oral suspension formulation American Journal of Hospital Pharmacy 36(5): 600
Batzer, F.R. 1984: Formulation and noncontraceptive uses of the new, low-dose oral contraceptive Journal of Reproductive Medicine 29(7 Suppl): 503-512
1985: WHO and UNICEF recommend new oral rehydration salts (ORS) formulation Bulletin of the Pan American Health Organization 19(1): 99-101
Holt, D.W.; Mueller, E.A.; Kovarik, J.M.; van Bree, J.B.; Richard, F.; Kutz, K. 1995: Sandimmun neoral pharmacokinetics: impact of the new oral formulation Transplantation Proceedings 27(1): 1434-1437
Mueller, B.A.; Rex, D.K.; Figueroa, N.; Greene, P.; Brater, D.C. 1992: A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation PharmacoTherapy 12(2): 93-97
Kovarik, J.M.; Mueller, E.A.; Johnston, A.; Hitzenberger, G.; Kutz, K. 1993: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation PharmacoTherapy 13(6): 613-617
Speroff, L. 1982: The formulation of oral contraceptives: does the amount of estrogen make any clinical difference? Johns Hopkins Medical Journal 150(5): 170-176
Foradori, A.C.; Martínez, L.; Vacarezza, A.; Elberg, L.; Loveluck, A.; Pinto, C. 1994: Pharmacokinetics of a new galenical formulation of oral cyclosporine a in stable kidney transplanted patients Transplantation Proceedings 26(5): 2969-2972
Anastasio, P.; Carazzone, M.; Pongiluppi, S. 1988: The microbiologic quality of an oral preparation as the result of proper formulation and technological design Bollettino Chimico Farmaceutico 127(11-12): 245-248
Kuhnz, W.; al-Yacoub, G.; Fuhrmeister, A. 1992: Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation Contraception 46(5): 455-469